Here, we highlight the possible implications of targeting ETs, especially METS, through the Syk-p38MAPK-dependent pathway in FcγRIIb−/− lupus mice that might develop novel therapeutic strategies against active lupus. Here, SYK is linked to systemic lupus erythematosus.